|
|
||||||||
Short Communication |
1 pleckstrin homology domain results in infectious pseudovirion production
1 AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
2 Kitasato Institute of Life Sciences, Kitasato University, Shirokane 5-9-1, Minato-ku, Tokyo 108-8641, Japan
Correspondence
Jun Komano
ajkomano{at}nih.go.jp
| ABSTRACT |
|---|
|
|
|---|
1 pleckstrin homology (PH) domain. PH–Gag–Pol PM targeting and viral production efficiencies were improved compared with Gag–Pol, consistent with the estimated increases in Gag–PM affinity. Both virions were recovered in similar sucrose density-gradient fractions and had similar mature virion morphologies. Importantly, PH–Gag–Pol and Gag–Pol pseudovirions had almost identical infectivity, suggesting a dispensable role for myristoylation in the virus life cycle. PH–Gag–Pol might be useful in separating the myristoylation-dependent processes from the myristoylation-independent processes. This the first report demonstrating infectious pseudovirion production without myristoylated Pr55Gag. | MAIN TEXT |
|---|
|
|
|---|
We constructed a mutant gag expression plasmid where the myristoylated region of Gag was replaced with the N-terminal pleckstrin homology (PH) domain of phospholipase C-
1 (PLC
1), a well-studied cellular PM-targeting motif that functions similarly to the myristoyl moiety. PLC
1 is a member of a family of inositol phospholipid-specific PLC isozymes involved in transducer-mediated intracellular responses (Berridge, 1993
). The
120 aa PH domain can bind to phosphatidylinositol 4,5-biphosphate [PI(4,5)P(2)] and localize to the PM with high affinity and specificity (Ferguson et al., 1995b
; Fiorentini et al., 2006
; Harlan et al., 1994
, 1995
; Rhee, 2001
; Yagisawa et al., 1994
), and green fluorescent protein-bound PLC
1 PH domains have been used to visualize the PM in living cells (Stauffer et al., 1998
; Tall et al., 2000
).
We used a codon-optimized HIV-1 gag–pol expression vector (pgag–pol) for genetic modification of gag, as pgag–pol increases Gag expression and facilitates protein analyses (Wagner et al., 2000
). The substituted mutant retained an intact MA, with the exception of two N-terminal amino acid mutations (ATG
CTG and GGC
GCG), resulting in an MG
LA mutation to knock out the myristoylation signal of Gag and prevent internal translational initiation (Fig. 1a
). The PLC
1 PH domain residues 1–175 (Stauffer et al., 1998
) were linked to the LA–Gag N terminus by the amino acids PRAEFT, creating a PH–gag–pol expression vector (pPH-gag-pol, Fig. 1a
). A control PH domain mutant (PH4A) had mutations at aa 54–57 (ESRK
AAAA; Fig. 1a
); these residues are responsible for the PH domain–PI(4,5)P(2) interaction (Ferguson et al., 1995a
). PH–Gag, PH4A–Gag and their cleaved products were detected in transfected 293T cell lysates with mouse monoclonal antibodies specific for the p24CA (capsid) domain (anti-p24CA; NIH AIDS Research and Reference Reagent Program) and MA domain (anti-p17MA; Advanced Biotechnologies) (Fig. 1b
). PH–Gag cleavage was more efficient than that of Gag, suggesting efficient PM targeting of PH–Gag (Fig. 1b
). The Gag protein levels in the pPH4A-gag-pol-transfected cell lysate were higher than those in pgag-pol- and pPH-gag-pol-transfected cell lysates when adjusted for the amount of protein loaded, indicating the low virus-like particle (VLP) production efficiency by PH4A–Gag (Fig. 1b
).
|
VLP production was also examined. Tissue culture supernatants of pgag-pol-, pPH-gag-pol- or pPH4A-gag-pol-transfected 293T cells were passed through nitrocellulose filters (0.45 µm) and the virions were collected by centrifugation (541 000 g for 1 h). Viral antigens, except for PH4A, were detected with anti-p24CA and anti-p17MA antibodies (Fig. 1b
). Gag and PH–Gag were further processed by the viral proteases in the virions compared with the cell lysates, as indicated by the increased signals for CA and MA relative to Gag. Interestingly, approximately one-fifth of the PH–Gag in the virion was cleaved close to the PH–MA junction. Presumably, the amino acid sequence at the C end of the PH domain ELQN/FLKE (aa 164–171, where the protease cleaves at the N–F junction) served as a viral protease recognition site as it matched the substrate consensus sequence and resembled the NC–p1 junction, RQAN/FLGK (de Oliveira et al., 2003
; Swanstrom & Wills, 1997
). Alternatively, the N terminus of LA–Gag (EFTL/AADS) might be targeted by the viral protease. Thus, the MA released from PH–MA, designated MA*, possibly has 10 aa attached to its N terminus.
The VLP production efficiency was quantified as the concentration of CA in transfected 293T cell culture supernatants relative to that in cell lysates using a p24 ELISA (Zeptometrics). When the CA concentrations of the virion fractions were normalized to those of the cell lysates, the pPH-gag-pol viral production efficiency was 3.2-fold higher than that of pgag-pol (3.2±2.0-fold, n=14, P<0.001 by Wilcoxon's matched pairs rank test; representative experiments are shown in Table 1
). In contrast, pPH4A-gag-pol produced viral particles less efficiently than pgag-pol (0.09±0.07-fold, n=6, P<0.05 by Wilcoxon's matched pairs rank test; representative experiments are shown in Table 1
). These data were consistent with the Western blot analysis (Fig. 1b
).
|
|
1 PH domain can functionally replace the HIV-1 Gag myristoylation signal to support both viral production and entry processes, and this myristoylation is dispensable for MA function in the early phase of the virus life cycle. This is the first report describing an infectious pseudovirion without myristoylated Gag. Given that PH–Gag can enhance virus production, HIV-1 with PH–Gag might have been expected to be selected in nature. This is not the case, presumably because the addition of PH to the HIV-1 genome would increase its genome size close to the upper limit that can be incorporated into the retroviral particle, leading to a decrease in genome uptake efficiency, which is clearly a growth disadvantage, despite the enhanced virus production with PH-Gag. More importantly, PH–Gag is unable to incorporate HIV-1 Env efficiently enough to support the production of fully infectious virions. Our data point to the selective advantage of myristoylated Gag in viral evolution.
The myristoylation-dependent Gag–PM association [maximal dissociation constant (Kd) of
0.5–1.0x10–5 M] is presumably important for Gag multimerization at the PM (Provitera et al., 2006
). After the first contact of Gag with the PM, the membrane binding of Gag is assumed to be stabilized by the Gag–PI(4,5)P(2) interaction (Ono et al., 2004
; Saad et al., 2006
). The multimerization of Gag appears to induce a conformational change in MA to expose myristoyl groups to enhance the PM targeting of Gag. The higher-order Gag multimerization is probably facilitated by the increased local concentrations of Gag at the PM. Although Gag and PH–Gag are similar to the extent that PI(4,5)P(2) is involved in their PM association, Gag binds to one of the acyl chains of PI(4,5)P(2), as modelled previously (Saad et al., 2006
), whilst the PH domain binds the phosphorylated inositol group (Lemmon et al., 1995
). The Kd of binding between the PLC
1 PH domain and PI(4,5)P(2) (
1–2x10–6 M; Lemmon et al., 1995
) suggests that the primary force driving PH–Gag to the PM is at least 2.5-fold stronger than that of myristoylation-mediated PM targeting of Gag. This might be one reason why PH–Gag–Pol was 3.2-fold more efficient at virion production than Gag–Pol. Our data suggest that the myristoyl group-dependent Gag–PM affinity is not a prerequisite for efficient Gag assembly at the PM or for viral production.
The MA has multiple functions throughout the virus life cycle (reviewed by Bukrinskaya, 2007
; Fiorentini et al., 2006
; Hearps & Jans, 2007
; Klein et al., 2007
). In the PH–Gag–Pol virion, approximately one-fifth of the PH–MA was unanchored from the PM as MA* (Fig. 1b
), which might accompany the pre-integration complex to support nuclear targeting. Using PH–Gag–Pol might enable separation of myristoylation-dependent and -independent MA functions, particularly during the entry phase. PH–Gag–Pol might also be useful for producing high-titre lentiviral vectors or for studying Gag trafficking in cells that poorly support PM targeting of myristoylated Gag, such as rodent cells. Furthermore, functional assays comparing the virus production of Gag–Pol and PH–Gag–Pol might enable the identification of chemical inhibitors or cellular factors specifically targeting myristoylated Gag.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Bryant, M. & Ratner, L. (1990). Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87, 523–527.
Bukrinskaya, A. (2007). HIV-1 matrix protein: a mysterious regulator of the viral life cycle. Virus Res 124, 1–11.[CrossRef][Medline]
de Oliveira, T., Engelbrecht, S., Janse van Rensburg, E., Gordon, M., Bishop, K., zur Megede, J., Barnett, S. W. & Cassol, S. (2003). Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J Virol 77, 9422–9430.
Ferguson, K. M., Lemmon, M. A., Schlessinger, J. & Sigler, P. B. (1995a). Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. Cell 83, 1037–1046.[CrossRef][Medline]
Ferguson, K. M., Lemmon, M. A., Sigler, P. B. & Schlessinger, J. (1995b). Scratching the surface with the PH domain. Nat Struct Biol 2, 715–718.[CrossRef][Medline]
Fiorentini, S., Marini, E., Caracciolo, S. & Caruso, A. (2006). Functions of the HIV-1 matrix protein p17. New Microbiol 29, 1–10.[Medline]
Futahashi, Y., Komano, J., Urano, E., Aoki, T., Hamatake, M., Miyauchi, K., Yoshida, T., Koyanagi, Y., Matsuda, Z. & Yamamoto, N. (2007). Separate elements are required for ligand-dependent and -independent internalization of metastatic potentiator CXCR4. Cancer Sci 98, 373–379.[CrossRef][Medline]
Göttlinger, H. G., Sodroski, J. G. & Haseltine, W. A. (1989). Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86, 5781–5785.
Harlan, J. E., Hajduk, P. J., Yoon, H. S. & Fesik, S. W. (1994). Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature 371, 168–170.[CrossRef][Medline]
Harlan, J. E., Yoon, H. S., Hajduk, P. J. & Fesik, S. W. (1995). Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate. Biochemistry 34, 9859–9864.[CrossRef][Medline]
Hearps, A. C. & Jans, D. A. (2007). Regulating the functions of the HIV-1 matrix protein. AIDS Res Hum Retroviruses 23, 341–346.[CrossRef][Medline]
Jouvenet, N., Neil, S. J., Bess, C., Johnson, M. C., Virgen, C. A., Simon, S. M. & Bieniasz, P. D. (2006). Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol 4, e435[CrossRef][Medline]
Kiernan, R. E., Ono, A., Englund, G. & Freed, E. O. (1998). Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 72, 4116–4126.
Klein, K. C., Reed, J. C. & Lingappa, J. R. (2007). Intracellular destinies: degradation, targeting, assembly, and endocytosis of HIV Gag. AIDS Rev 9, 150–161.[Medline]
Komano, J., Miyauchi, K., Matsuda, Z. & Yamamoto, N. (2004). Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses. Mol Biol Cell 15, 5197–5207.
Lemmon, M. A., Ferguson, K. M., O'Brien, R., Sigler, P. B. & Schlessinger, J. (1995). Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc Natl Acad Sci U S A 92, 10472–10476.
Ono, A., Ablan, S. D., Lockett, S. J., Nagashima, K. & Freed, E. O. (2004). Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A 101, 14889–14894.
Pal, R., Reitz, M. S., Jr, Tschachler, E., Gallo, R. C., Sarngadharan, M. G. & Veronese, F. D. (1990). Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly. AIDS Res Hum Retroviruses 6, 721–730.[Medline]
Provitera, P., El-Maghrabi, R. & Scarlata, S. (2006). The effect of HIV-1 Gag myristoylation on membrane binding. Biophys Chem 119, 23–32.[CrossRef][Medline]
Rhee, S. G. (2001). Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70, 281–312.[CrossRef][Medline]
Saad, J. S., Miller, J., Tai, J., Kim, A., Ghanam, R. H. & Summers, M. F. (2006). Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A 103, 11364–11369.
Scholz, I., Still, A., Dhenub, T. C., Coday, K., Webb, M. & Barklis, E. (2008). Analysis of human immunodeficiency virus matrix domain replacements. Virology 371, 322–335.[Medline]
Stauffer, T. P., Ahn, S. & Meyer, T. (1998). Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. Curr Biol 8, 343–346.[CrossRef][Medline]
Swanstrom, R. & Wills, J. W. (1997). Synthesis, assembly, and processing of viral proteins. In Retroviruses, pp. 263–334. Edited by J. M. Coffin, S. H. Hughes & H. Varmus. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
Tall, E. G., Spector, I., Pentyala, S. N., Bitter, I. & Rebecchi, M. J. (2000). Dynamics of phosphatidylinositol 4,5-bisphosphate in actin-rich structures. Curr Biol 10, 743–746.[CrossRef][Medline]
Wagner, R., Graf, M., Bieler, K., Wolf, H., Grunwald, T., Foley, P. & Uberla, K. (2000). Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 11, 2403–2413.[CrossRef][Medline]
Wang, C. T., Zhang, Y., McDermott, J. & Barklis, E. (1993). Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant. J Virol 67, 7067–7076.
Yagisawa, H., Hirata, M., Kanematsu, T., Watanabe, Y., Ozaki, S., Sakuma, K., Tanaka, H., Yabuta, N., Kamata, H. & other authors (1994). Expression and characterization of an inositol 1,4,5-trisphosphate binding domain of phosphatidylinositol-specific phospholipase C-
1. J Biol Chem 269, 20179–20188.
Zhou, W., Parent, L. J., Wills, J. W. & Resh, M. D. (1994). Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 68, 2556–2569.
Received 11 June 2008;
accepted 20 August 2008.
This article has been cited by other articles:
![]() |
T. Murakami, S. Kumakura, T. Yamazaki, R. Tanaka, M. Hamatake, K. Okuma, W. Huang, J. Toma, J. Komano, M. Yanaka, et al. The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100 Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2940 - 2948. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |